top of page
Executive Spotlights

Marea Therapeutics Secures $190M to Lead Genetic Breakthroughs in Cardiometabolic Medicine

South San Francisco, CA, June 18, 2024 (Business Wire) -- Marea Therapeutics, raises $190 million from leading investors, to pioneer advancements in cardiometabolic medicine. The funding supports Phase 2 trials for its lead program, MAR001, a monoclonal antibody targeting a key protein in fat metabolism. Incubated by Third Rock Ventures, Marea is poised to innovate in the genetic treatment of cardiometabolic diseases.

Read full article here.

Recent Posts

See All

Radiant Vision Systems Appoints new CEO

Redmond, WA, July 1, 2024 (Radiant) -- Radiant Vision Systems has appointed Stone Jiang as their new CEO, succeeding Doug Kreysar who is retiring. Jiang, previously the Executive Vice President and

Orion and Merck Secure $1.63B Agreement

Rahway, NJ, July 1, 2024 (Business Wire) -- Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, and Orion Corporation ("Orion") have agreed to convert their co-development and co-commercial


Life Science Headlines
bottom of page